mercurius-adept schreef op 12 juli 2021 20:17:
Bone Therapeutics heeft Anne Leselbaum vandaag benoemd tot Chief Medical Officer, per 23 Augustus 2021...www.beursduivel.be/nieuws/723929/Bone...
-->maar dan verder lezende wordt het eigenlijk nog intrigerender:
Miguel Forte, CEO, Bone Therapeutics:
“Anne Leselbaum has extensive professional experience in bringing advanced therapeutics through the clinical stage to marketing authorization. This includes her experience with Takeda’s approved allogeneic cell therapy product, Alofisel. In addition to her experience of building strong connections with key opinion leaders, her interactions and existing relationships with regulators, specifically the EMA and FDA will also be vital at this stage.”
Anne Leselbaum, MD:
“Whilst the cell and gene therapy sector continues to develop, joining Bone Therapeutics, which is seeking to commercialize one therapy whilst moving into whole new areas of cutting edge research and clinical development
is an excellent opportunity"